At the dosage of 2 g/day , strontium ranelate was associated with greater response than placebo in terms of 20 % improvement in WOMAC pain from baseline to the last visit ( 58 % vs 47 % , P = 0.002 ) and 50 % improvement in WOMAC pain ( 42 % vs 36 % , P = 0.083 ) .